The results of a UK study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) showed that tumour necrosis factor inhibitor (anti-TNF) treatment is effective at improving both muscle and
skin involvement in children with juvenile dermatomyositis (JDM).
So, we are addressing, specifically, inoperable cases due to
extensive skin involvement, fixed or very bulky axillary nodal disease and / or supraclavicular or internal mammary nodal involvement or tumors with inflammatory elements.»
There were also significant improvements in
skin involvement assessed using the modified skin Disease Activity Score (p < 0.0001).
Any distribution
of skin involvement may occur, but the ears, rump, limbs, axillae (arm pits) and groin are commonly affected.
Evaluation of 66 patients with JDM, recruited from the UK JDM Cohort and Biomarker Study and actively treated with anti-TNF agents, showed significant improvements in muscle and
skin involvement, as well as in overall disease activity.
Mast cell tumors do not have to involve the skin and can develop internally but most of the time there is
skin involvement.
Sine Scleroderma where there's
no skin involvement and just organ involvement will be a decline for traditional carriers.